|Other Names||Diacylglycerol kinase alpha, DAG kinase alpha, 80 kDa diacylglycerol kinase, Diglyceride kinase alpha, DGK-alpha, DGKA, DAGK, DAGK1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8128a was selected from the N-term region of human DGKA . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Upon cell stimulation converts the second messenger diacylglycerol into phosphatidate, initiating the resynthesis of phosphatidylinositols and attenuating protein kinase C activity.|
|Tissue Location||Lymphocytes and oligodendroglial cells.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Upon cell stimulation, the kinase DGKA converts the second messenger diacylglycerol into phophatidate, initiating the resynthesis of phosphatidylinositols and attenuating protein kinase C activity. DGKA is stimulated by calcium and phosphatidylserine, and is phosphorylated by protein kinase C. Tissue expression is in lymphocytes and oligodengroglial cells. DGKA contains 2 zinc-dependent phorbol-ester and DAG binding domains, and 2 EF-hand calcium binding domains.
Hart, T.C., et al., Genomics 22(1):246-247 (1994).Hart, T.C., et al., Mamm. Genome 5(2):123-124 (1994).Schaap, D., et al., FEBS Lett. 275 (1-2), 151-158 (1990).
If you have any additional inquiries please email technical services at email@example.com.